EUVIMEDDescubrir EUVIMED
KommentarOpen access · CC BY 4.0

Cancer‐associated fibroblast heterogeneity in chordoma †

Jack C Henry iD, Angus J M Cameron iD

The Journal of Pathology · 2025

DOI: 10.1002/path.6420 ↗

At a glance

Kommentar in The Journal of Pathology, 2025. Written by Jack C Henry and 1 co-authors. Institution: Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, UK. Major MEDLINE topics: Chordoma, Cancer-Associated Fibroblasts. 11 references. The full text is freely available (open access, CC BY 4.0). Funded by: Medical Research Council, Cancer Research UK.

ResumenSubjectsDatos bibliográficosCiteRelated studies

Abstract (original language)

In solid tumours, malignant cells develop relationships with nonmalignant stromal cells to support tumour growth, tissue structure, and nutrient supply. In a recent issue of this journal, Zheng and Guo catalogue the cellular landscape in chordoma using a combination of single‐cell and spatial transcriptomics. Despite the mesenchymal nature of chordoma, malignant cells retain expression of epithelial markers, in addition to mesenchymal, partial‐EMT, and stem‐cell signatures. Cancer‐associated fibroblasts (CAFs) are among the most abundant stromal cells and the authors define an inflammatory CAF subtype (iCAF), which is associated with poor outcome and tumour invasion. It is proposed that iCAFs arise from normal fibroblasts during malignant tumour progression and play a causative role in driving an invasive poor prognosis tumour phenotype. Recent reports by this and other groups have separately catalogued cell populations, including CAFs and immune cells in chordoma. The next challenge will be to integrate findings from these distinct studies to allow a consensus to be reached regarding cellular heterogeneity within chordoma, and to allow comparison of CAF populations with those found in other tumour types. Comparison of CAF functions in these predominantly mesenchymal tumours with epithelial solid tumours may reveal interesting lessons about the diverse phenotypes CAFs can bring to distinct tumour ecosystems. Understanding the role of CAFs in chordoma progression may also lead to therapeutic opportunities, but separation of correlation and causation in CAF regulation of tumour phenotypes remains a significant challenge. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

ChordomaCancer-Associated FibroblastsHumansTumor MicroenvironmentBiomarkers, TumorPhenotype

Author keywords

cancer‐associated fibroblastschordomasingle‐cell transcriptomicsspatial transcriptomicstumour invasion

Substances

Biomarkers, Tumor

Authors and institutions

  • Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, UK.

ORCID profiles: Jack C Henry, Angus J M Cameron

Funding

  • Medical Research Council
  • Cancer Research UK

Cite

APA

Henry, J. C., & Cameron, A. J. M. (2025). Cancer‐associated fibroblast heterogeneity in chordoma †. The Journal of Pathology. https://doi.org/10.1002/path.6420

Vancouver

Henry JC, Cameron AJM. Cancer‐associated fibroblast heterogeneity in chordoma †. The Journal of Pathology. 2025. doi:10.1002/path.6420

BibTeX
@article{Henry2025,
  author = {Henry, Jack C and Cameron, Angus J M},
  title = {Cancer‐associated fibroblast heterogeneity in chordoma †},
  journal = {The Journal of Pathology},
  year = {2025},
  doi = {10.1002/path.6420}
}
Start for free →